Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baminercept (BG9924) dose-escalation in active rheumatoid arthritis
NCT00292422Phase 2Completed
- Sponsor
- Biogen
- Start
- Nov 2005
- Primary completion
- May 2007
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing BG9924 + MTX with Placebo + MTX (2 arms). Primary endpoint: Safety and tolerability of BG9924 in combination with MTX. Started Nov 2005; status: completed.
02
Drugs
baminercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00292422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292422.